Pulse Biosciences, Inc. (PLSE) Financial Analysis & Valuation | Quarter Chart

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue t... more
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a... more

Company facts

Reported company information and share structure.

Company Share structure
Market Cap$3.73BExchangeNASDAQ
SectorHealthcareIndustryMedical - Instruments & Supplies
CountryUSCEOPaul Arthur LaViolette
IPO Date2016-05-18CAGR
Employees116Websitewww.pulsebiosciences.com
Div. YieldPayout Ratio
Buy Back YieldTotal Yield
PLSE chart loading...

Key metrics

Reported fundamentals and market-derived technical indicators.

Fundamentals Technicals
EV$2.58BP/E-45.65Forward P/E-46.71PEG
P/S133656.37P/B1591.4P/CF-2092.54P/FCF-2082.31
Sales$1.19MSales 1Yinf%Sales 3Y-13266.67%Sales 5Yinf%
EPS$-1.18EPS 1Y9.35%EPS 3Y-4.88%EPS 5Y-50%
Sales QoQ8.23%EPS QoQ38.46%Sales QoQ AvgEPS QoQ Avg7.92%
Gross Margin-21.6%Operating Margin-7007.76%Profit Margin-6755.78%ROCE-79.4%
ROA-69%ROE-94%Altman Z Score119.58Piotroski Score3
Current Ratio9.63Quick Ratio9.61Cash Ratio9.26Op. CF Ratio-3.03
Debt/Equity0.07Debt/Assets0.06Lt Debt/Equity0.05Lt Debt/Cap.0.05
Intrst Cov.Inventory Turnover6.11Asset Turnover0.01Receivables Turnover9.71
Enterprise Value$2.58BP/E Ratio-45.65
Forward P/E-46.71PEG Ratio
P/S Ratio133656.37P/B Ratio1591.4
P/CF Ratio-2092.54P/FCF Ratio-2082.31
EPS$-1.18EPS Growth 1Y9.35%
EPS Growth 3Y-4.88%EPS Growth 5Y-50%
Revenue Growth 1Yinf%Gross Margin-21.6%
Operating Margin-7007.76%Profit Margin-6755.78%
ROE-94%ROA-69%
ROCE-79.4%Current Ratio9.63
Quick Ratio9.61Cash Ratio9.26
Debt/Equity0.07Interest Coverage
Altman Z Score119.58Piotroski Score3